2020

CSI Singapore Clinches Multiple Awards at NCAM 2020 Digital Meeting

August 6, 2020

The 7th NCSIS Annual Research Meeting (NCAM) 2020 recently concluded its first digital meeting. Co-organised by National University Cancer Institute (NCIS) and CSI Singapore, the NCAM 2020 Digital Meeting hosted a total of 727 attendees from 58 institutions. The theme for this year’s meeting is ‘Cancer Care: From Bench to Bedside’. Held from 22 July – […]

Read More
Aug 06, 2020 Celine Tam 0 comments
Novel Digital Medicine Platform Offers New Hope for Lymphoma Patients

July 25, 2020

Researchers from Cancer Science Institute of Singapore (CSI Singapore) and National University Cancer Institute of Singapore (NCIS) recently harnessed the Quadratic Phenotypic Optimisation Platform (QPOP), an AI-driven digital medicine platform, to revolutionize the treatment for lymphoma. Developed by a research team led by CSI Singapore Principal Investigator, Associate Professor Edward Chow, QPOP leverages artificial intelligence […]

Read More
Jul 25, 2020 Celine Tam 0 comments
Congratulations to Prof. Toshio Suda for being awarded the 2020 E. Donnall Thomas Lecture and Prize!

July 2, 2020

CSI Singapore is pleased to announce that Senior Principal Investigator, Prof. Toshio Suda, has been awarded the 2020 E. Donnall Thomas Lecture and Prize for his outstanding contributions to the field of stem cell research. Prof. Suda will present his lecture at the 62nd ASH Annual Meeting and Exposition. Established in 1992, this lectureship and […]

Read More
Jul 02, 2020 Celine Tam 0 comments
Congratulations to Dr. Takaomi Sanda on his promotion to Associate Professor!

May 14, 2020

CSI Singapore is proud to announce the promotion of Dr. Takaomi Sanda to Associate Professor. Dr. Sanda joined CSI Singapore in 2013 as a Principal Investigator. Since then, he has achieved an impressive track record in his research studies, which mostly focus on T-cell acute lymphoblastic leukemia (T-ALL) and other lymphoid malignancies. Please join us […]

Read More
May 14, 2020 Celine Tam 0 comments
IDentif.AI: Artificial Intelligence Pinpoints Remdesivir in Combination with Ritonavir and Lopinavir as an Optimal Regimen Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

May 12, 2020

CSI Principal Investigator, A/Professor Edward Chow was recently involved in an impactful study led by Professor Dean Ho. The team reported the use of Identif.AI, a platform that rapidly optimizes infectious disease (ID) combination therapy design using artificial intelligence. In the study, IDentif.AI was implemented on a 12-drug candidate therapy search set representing over 530,000 […]

Read More
May 12, 2020 Celine Tam 0 comments